Sirintra Nakjang

Sirintra Nakjang

Auto-generated profile, based on publicly available information

Sirintra Nakjang

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
HIHasan Issa
Hasan Issa
LSLaura E. Swart
Laura E. Swart
MRMilad Rasouli
Milad Rasouli
MAMinoo Ashtiani
Minoo Ashtiani
SNSirintra Nakjang
Sirintra Nakjang
OHOlaf Heidenreich
Olaf Heidenreich
A hallmark of acute myeloid leukaemias (AMLs) are chromosomal rearrangements that give rise to novel leukaemia-specific fusion genes. Most of these fusion genes are both initiating and driving events in AML and therefore constitute ideal therapeutic targets but are challenging to target by conventional drug development. siRNAs are frequently used for the specific suppression of fusion gene expression but require special formulations for efficient in vivo delivery. Here we describe the use of siRNA-loaded lipid nanoparticles for the specific therapeutic targeting of the leukaemic fusion gene RUNX1/ETO. Transient knockdown of RUNX1/ETO reduces its binding to its target genes and alters the binding of RUNX1 and its co-factor CBFβ. Transcriptomic changes in vivo were associated with substantially increased median survival of a t(8;21)-AML mouse model. Importantly, transient knockdown in vivo causes long-lasting inhibition of leukaemic proliferation and clonogenicity, induction of myeloid differentiation and a markedly impaired re-engraftment potential in vivo. These data strongly suggest that temporary inhibition of RUNX1/ETO results in long-term restriction of leukaemic self-renewal. Our results provide proof for the feasibility of targeting RUNX1/ETO in a pre-clinical setting and support the further development of siRNA-LNPs for the treatment of fusion gene-driven malignancies.

20 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
DODaniel O’neill
Daniel O’neill
DJDominic Jones
Dominic Jones
MWMark Wade
Mark Wade
JGJames Grey
James Grey
SNSirintra Nakjang
Sirintra Nakjang
LGLuke Gaughan
Luke Gaughan
Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy